Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Management of statin-intolerant patient.

Arca M, Pigna G, Favoccia C.

Panminerva Med. 2012 Jun;54(2):105-18. Review.

PMID:
22525565
2.

Treating statin-intolerant patients.

Arca M, Pigna G.

Diabetes Metab Syndr Obes. 2011;4:155-66. doi: 10.2147/DMSO.S11244. Epub 2011 Apr 28.

3.

Management of the patient with statin intolerance.

Vandenberg BF, Robinson J.

Curr Atheroscler Rep. 2010 Jan;12(1):48-57. doi: 10.1007/s11883-009-0077-8. Review.

PMID:
20425271
5.

Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.

Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, Moriarty PM.

Ann Pharmacother. 2008 Mar;42(3):341-6. doi: 10.1345/aph.1K604. Epub 2008 Feb 19.

PMID:
18285559
6.

Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia.

Harris LJ, Thapa R, Brown M, Pabbathi S, Childress RD, Heimberg M, Braden R, Elam MB.

J Clin Lipidol. 2011 Jul-Aug;5(4):299-307. doi: 10.1016/j.jacl.2011.05.005. Epub 2011 Jun 12.

PMID:
21784376
7.

Management of statin-intolerant high-risk patients.

Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP.

Curr Vasc Pharmacol. 2010 Sep;8(5):632-7. Review.

PMID:
20507273
8.

[Adverse effects of statins].

Andréjak M, Gras V, Massy ZA, Caron J.

Therapie. 2003 Jan-Feb;58(1):77-83. Review. French.

PMID:
12822204
9.

Strategies to preserve the use of statins in patients with previous muscular adverse effects.

Reinhart KM, Woods JA.

Am J Health Syst Pharm. 2012 Feb 15;69(4):291-300. doi: 10.2146/ajhp100700. Review.

PMID:
22302254
10.

The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.

Degreef LE, Opdam FL, Teepe-Twiss IM, Jukema JW, Guchelaar HJ, Tamsma JT.

Eur J Intern Med. 2010 Aug;21(4):293-6. doi: 10.1016/j.ejim.2010.03.015. Epub 2010 May 13.

PMID:
20603038
11.

Managing the underestimated risk of statin-associated myopathy.

Rallidis LS, Fountoulaki K, Anastasiou-Nana M.

Int J Cardiol. 2012 Sep 6;159(3):169-76. doi: 10.1016/j.ijcard.2011.07.048. Epub 2011 Aug 2. Review.

PMID:
21813193
12.

Managing statin myopathy.

Venero CV, Thompson PD.

Endocrinol Metab Clin North Am. 2009 Mar;38(1):121-36. doi: 10.1016/j.ecl.2008.11.002. Review.

PMID:
19217515
13.

Risks associated with statin therapy: a systematic overview of randomized clinical trials.

Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM.

Circulation. 2006 Dec 19;114(25):2788-97. Epub 2006 Dec 11. Review.

14.

Statin-induced myopathy: a review and update.

Abd TT, Jacobson TA.

Expert Opin Drug Saf. 2011 May;10(3):373-87. doi: 10.1517/14740338.2011.540568. Epub 2011 Feb 23. Review.

PMID:
21342078
15.

Management of the statin-intolerant patient.

Smiley III WH, Khan BV, Sperling LS.

Curr Treat Options Cardiovasc Med. 2009 Aug;11(4):263-71.

PMID:
19627659
16.

The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.

Harper CR, Jacobson TA.

Curr Opin Lipidol. 2007 Aug;18(4):401-8. Review.

PMID:
17620856
17.

Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.

Keating AJ, Campbell KB, Guyton JR.

Ann Pharmacother. 2013 Mar;47(3):398-404. doi: 10.1345/aph.1R509. Epub 2013 Mar 12. Review.

PMID:
23482733
19.

[Statin myopathy--rarity or reality?].

Pella D.

Vnitr Lek. 2010 Sep;56(9 Suppl):972-6. Review. Slovak.

PMID:
21137170
20.

Supplemental Content

Support Center